Olaparib Shows PFS Benefit at 5-Year Follow-Up in BRCA Ovarian Cancer

Article

Patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who experienced complete or partial response following platinum-based chemotherapy continued to exhibit benefit in progression-free survival when receiving olaparib at long-term follow up versus placebo as first-line maintenance.

José Baselga, MD

Patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who experienced complete or partial response following platinum-based chemotherapy continued to exhibit benefit in progression-free survival (PFS) when receiving olaparib (Lynparza) at long-term follow up versus placebo as first-line maintenance, according to a press release from AstraZeneca.1

With 5-year follow-up, the SOLO-1 trial [NCT01844986] has the longest follow-up analysis for any PARP inhibitor used in as first-line maintenance.

“Once a patient’s ovarian cancer recurs, it historically has been incurable,” José Baselga, MD, PhD, executive vice president of Oncology Research & Development, said in a statement. “Even at an advanced stage, we have shown that maintenance treatment with Lynparza can help patients achieve sustained remission. [These] results further underline the critical importance of identifying a patient’s biomarker status at the time of diagnosis to offer a treatment that may help delay disease progression.”

On this phase 3, double-blind, placebo controlled, multicenter trial of olaparib, patients had a median PFS of 56.0 months compared with 13.8 months on placebo at 5 years. Olaparib reduced the risk of disease progression or death by 67% (HR, 33%; 95% CI, 0.25-0.43). There were 48.3% of patients who did not have disease progression when receiving olaparib versus 20.5% for patients receiving placebo.

There was a median recurrence-free survival was not reached by the time of this follow-up versus a median of 15.3 with placebo (HR, 0.37; 95% CI, 0.27-0.52). There was a median duration of treatment of 24.6-month with the PARP inhibitor compared with 13.9 months with placebo.

For olaparib, PFS went from 87.7% at 1 year, 73.6% at 2 years, 60.1% at 3 years, 52.3% at 4 years, to 48.3% at 5 years versus 51.4%, 34.6%, 26.9%, 21.5%, and 20.5% with placebo, respectively. The recurrence-free survival at years 1 through 5 for olaparib were 91.0%, 77.2%, 64.0%, 55.2%, and 51.9% compared with 58.0%, 39.0%, 28.9% 23.0%, and 21.8% for placebo.

Olaparib’s toxicity profile consisted of nausea in 77% of patients, fatigue/asthenia in 63%, vomiting in 40%, anemia in 39%, and diarrhea in 34% as the most common adverse events. The most common grade 3 and above events were anemia in 22% and neutropenia in 9% of patients. There were 12% of patients who discontinued treatment with olaparib due to an adverse event.

“For patients with newly diagnosed BRCA-mutated advanced ovarian cancer, the benefit derived from 2 years of maintenance treatment with Lynparza continued long after treatment ended,” Susana Banerjee, MBBS, MA, PhD, an investigator from the SOLO-1 trial and consultant medical oncologist at The Royal Marsden NHS Foundation Trust and Reader at The Institute of Cancer Research, London, said in a press release.

“After five years, almost half of women were free of cancer progression. These results represent a significant step forward in the treatment of BRCA-mutated advanced ovarian cancer,” she continued in her statement.

Olaparib was approved in the United States and multiple other countries after SOLO-1 met its primary end point in 2018.2

For the 391 patients on the trial randomized 2:1 to olaparib, treatment was given at 300 mg twice a day as maintenance monotherapy after they had received a platinum-based therapy in the front line. Treatment with olaparib or placebo was given for up to 2 years or until disease progression, and patients who had partial response at 2 years were allowed to stay on therapy at the investigator’s discretion.

“This is the first trial of a PARP inhibitor to read out a five year follow up and showed Lynparza improved PFS to over 4 and half years versus 13.8 months with placebo following response to 1st-line platinum-based chemotherapy. This latest data represents a major and significant milestone in a disease which has historically had such a poor prognosis,” Roy Baynes, MD, PhD, the senior vice president and head of Global Clinical Development, and chief medical officer at MSD Research Laboratories, said in a press release.

Reference:

1. Lynparza improved median time patients lived without disease progression to over four and half years in BRCA-mutated advanced ovarian cancer vs. just over one year with placebo. News release. AstraZeneca. Published September 18, 2020. Accessed September 18, 2020. https://bit.ly/2RB9cfA

2. FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers. FDA. Updated May 11, 2020. Accessed September 18, 2020. https://bit.ly/3hH0ffm

Recent Videos
Chad A. Hamilton, MD, an expert on ovarian cancer
Chad A. Hamilton, MD, an expert on ovarian cancer
Chad A. Hamilton, MD, an expert on ovarian cancer
Chad A. Hamilton, an expert on ovarian cancer
Chad A. Hamilton, MD, an expert on ovarian cancer
Chad A. Hamilton, an expert on ovarian cancer
Related Content